278 related articles for article (PubMed ID: 21464805)
1. Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis.
Salvati M; D'elia A; Frati A; Brogna C; Santoro A; Delfini R
J Neurosurg Sci; 2011 Mar; 55(1):1-6. PubMed ID: 21464805
[TBL] [Abstract][Full Text] [Related]
2. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.
Miglierini P; Bouchekoua M; Rousseau B; Hieu PD; Malhaire JP; Pradier O
Clin Neurol Neurosurg; 2012 Nov; 114(9):1222-5. PubMed ID: 22464950
[TBL] [Abstract][Full Text] [Related]
3. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Ashby LS; Smith KA; Stea B
World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
[TBL] [Abstract][Full Text] [Related]
4. The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma.
Barr JG; Grundy PL
Br J Neurosurg; 2012 Dec; 26(6):818-22. PubMed ID: 22715955
[TBL] [Abstract][Full Text] [Related]
5. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme.
McGirt MJ; Than KD; Weingart JD; Chaichana KL; Attenello FJ; Olivi A; Laterra J; Kleinberg LR; Grossman SA; Brem H; Quiñones-Hinojosa A
J Neurosurg; 2009 Mar; 110(3):583-8. PubMed ID: 19046047
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
7. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
8. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.
Westphal M; Ram Z; Riddle V; Hilt D; Bortey E;
Acta Neurochir (Wien); 2006 Mar; 148(3):269-75; discussion 275. PubMed ID: 16482400
[TBL] [Abstract][Full Text] [Related]
9. [Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas].
Yoshida M; Yamaguchi S; Ishi Y; Endo S; Motegi H; Kobayashi H; Asaoka K; Kamoshima Y; Terasaka S; Houkin K
No Shinkei Geka; 2015 Jul; 43(7):603-10. PubMed ID: 26136324
[TBL] [Abstract][Full Text] [Related]
10. Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme.
Smith KA; Ashby LS; Gonzalez LF; Brachman DG; Thomas T; Coons SW; Battaglia M; Scheck A
J Neurosurg; 2008 Dec; 109 Suppl():106-17. PubMed ID: 19123896
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Gururangan S; Cokgor L; Rich JN; Edwards S; Affronti ML; Quinn JA; Herndon JE; Provenzale JM; McLendon RE; Tourt-Uhlig S; Sampson JH; Stafford-Fox V; Zaknoen S; Early M; Friedman AH; Friedman HS
Neuro Oncol; 2001 Oct; 3(4):246-50. PubMed ID: 11584894
[TBL] [Abstract][Full Text] [Related]
12. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Noël G; Schott R; Froelich S; Gaub MP; Boyer P; Fischer-Lokou D; Dufour P; Kehrli P; Maitrot D
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):749-55. PubMed ID: 21300471
[TBL] [Abstract][Full Text] [Related]
13. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
14. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Menei P; Metellus P; Parot-Schinkel E; Loiseau H; Capelle L; Jacquet G; Guyotat J;
Ann Surg Oncol; 2010 Jul; 17(7):1740-6. PubMed ID: 20443147
[TBL] [Abstract][Full Text] [Related]
15. Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
Duntze J; Litré CF; Eap C; Théret E; Debreuve A; Jovenin N; Lechapt-Zalcman E; Metellus P; Colin P; Guillamo JS; Emery E; Menei P; Rousseaux P; Peruzzi P
Ann Surg Oncol; 2013 Jun; 20(6):2065-72. PubMed ID: 23212763
[TBL] [Abstract][Full Text] [Related]
16. A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas.
Aoki T; Nishikawa R; Sugiyama K; Nonoguchi N; Kawabata N; Mishima K; Adachi J; Kurisu K; Yamasaki F; Tominaga T; Kumabe T; Ueki K; Higuchi F; Yamamoto T; Ishikawa E; Takeshima H; Yamashita S; Arita K; Hirano H; Yamada S; Matsutani M;
Neurol Med Chir (Tokyo); 2014; 54(4):290-301. PubMed ID: 24739422
[TBL] [Abstract][Full Text] [Related]
17. The role of Gliadel wafers in the treatment of high-grade gliomas.
Bregy A; Shah AH; Diaz MV; Pierce HE; Ames PL; Diaz D; Komotar RJ
Expert Rev Anticancer Ther; 2013 Dec; 13(12):1453-61. PubMed ID: 24236823
[TBL] [Abstract][Full Text] [Related]
18. The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.
Xing WK; Shao C; Qi ZY; Yang C; Wang Z
Drug Des Devel Ther; 2015; 9():3341-8. PubMed ID: 26170620
[TBL] [Abstract][Full Text] [Related]
19. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
20. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
Durando X; Lemaire JJ; Tortochaux J; Van-Praagh I; Kwiatkowski F; Vincent C; Bailly C; Verrelle P; Irthum B; Chazal J; Bay JO
Bone Marrow Transplant; 2003 Apr; 31(7):559-64. PubMed ID: 12692621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
